Nature Biotechnology is encouraging authors of computational biology papers to publish their source code on GitHub as part of a company-wide drive to ensure research is reproducible. The policy is designed to counter long-standing concerns about the peer review of computation-heavy research.
Medidata has bolstered its books with two new deals. Accenture is tightening the ties between its R&D service offering and Medidata's Clinical Cloud and Rave EDC system.
The United Kingdom has wasted no time getting industry involved with its 100,000 Genomes Project. With just 3% of the sequencing work done, Genomics England has enlisted the help of a who's who of Big Pharma companies to pore over the data in search of new avenues for drug discovery.
Google has added another publicly available database to its growing Genomics platform. The latest deal sees Google Genomics host Tute Genomics' repository of 8.5 billion annotations of genetic variants, giving users another resource to probe with the tech giant's growing arsenal of data integration tools.
Apple is giving researchers the power to turn its 700 million iPhone users into participants in massive virtual trials. And the approach is already proving effective, with an iPhone-powered study of Parkinson's disease smashing the previous enrollment record by recruiting 7,406 participants in six hours.
Google has given the world a peek at one of the ways in which it thinks algorithms and huge datasets could reshape drug discovery. The work involves trying to make virtual drug screening more efficient using the same ethos Google applies to most problems: More data, more computing power.
LabCorp closed its $5.7 billion takeover of Covance this week and immediately began talking up the potential for its testing data to turbocharge the CRO's clinical trial business.
The Financial Times has taken a look inside Chinese sequencing giant BGI and the implications of its mission to sequence the genomes of one million humans, one million microorganisms and one million plants and animals.
Big Data initiatives such as President Obama's precision medicine program and the United Kingdom's 100,000 Genomes Project risk losing public trust unless they consider the moral and legal implications of their work, a report has warned.
President Obama has made the creation of a huge, technically challenging database the centerpiece of his precision medicine proposal. The initiative will draw on existing resources and new studies to gather data on the biology, behavior and health of more than 1 million people.